KIT and gastrointestinal stromal tumor: ETV1 may also be critical for the survival and maintenance of the intrinsically imatinib-resistant, KIT-independent stem cell/progenitors in GIST, suggesting that this may be a therapeutic target to consider in KIT wild-type GIST [32].